Conexeu Sciences, a preclinical-stage regenerative tissue platform company, debuted on Nasdaq, framing the public listing as a milestone for its mission of “Architecting Bioregeneration” and for the development of a platform designed to support the biological conditions needed to restore lost or damaged tissue. “At Conexeu, we believe regenerative medicine requires more than incremental improvement;…